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he Study of the Liver. PublishedSummary Aims: Taiwan implemented a comprehensive and universal National Health Insur-
ance (NHI) program to cover all inhabitants. This study aimed to assess the medical utilization
by liver cancer patients under the NHI.
Methods: This retrospective cross-sectional study used a sampled NHI research database,
which contained 1 million beneficiaries. The claims of liver cancer patients in 2009 were
analyzed. The other beneficiaries without liver cancer who used medical services in 2009
served as the control patients.
Results: Among the 2335 identified liver cancer patients, 2178 (93.3%) patients used outpa-
tient services and 1193 (51.1%) patients used inpatient services. Liver cancer accounted for
1.8% of the NHI’s total cost. The cost per visit was United States dollars (US$)59.30 for outpa-
tient care and US$2070.30 for inpatient care. The annual cost per patient was US$4746.60;
US$1951.00 were for outpatient care and US$2795.60 for inpatient care. Patients who were fe-
male, in their 60s, had a lower income, and lived in southern Taiwan had a higher cost per pa-
tient (p < 0.0001). Fees for consultation, treatment, and medical supplies (57.3%) accounted
for the highest portion of outpatient costs, followed by drug fees (30.0%) and diagnosis fees
(11.2%). Ward fees accounted for the highest portion of inpatient costs (19.0%), followed by
drug fees (18.7%) and X-ray fees (14.9%). Private hospitals were visited more frequently than
public hospitals. The cost per visit and cost per patient with liver cancer were 206.0% and
666.8%, respectively, of the cost of the control patients.astroenterology, Department of Internal Medicine, Cheng Hsin General Hospital, Number 45, Cheng-
n.
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geographic distribution. It is critical to reduce the incidence of liver cancer and identify
cost-effective treatment strategies.
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Liver cancer is a major cause of cancer mortality worldwide
[1]. Its incidence is increasing in Western countries, largely
because of infection by hepatitis B virus (HBV) and hepatitis
C virus (HCV) [2e4]. The prognosis is often poor for patients
with advanced symptomatic liver cancer. The burden of
liver cancer has increased. However, studies of medical
utilization by liver cancer patients are limited.
Taiwan is in a region of high incidence of liver cancer.
Liver cancer is the second leading cause of death in Taiwan
and caused 7809 deaths in 2007 [5]. The age standardized
incidence of liver cancer is 28.1 cases per 100,000 people.
Liver cancer accounted for 5.6% of deaths in the year 2007
in Taiwan. The National Health Insurance (NHI) is a
comprehensive and universal health insurance program that
has provided Western medicine and Chinese medicine since
1995 in Taiwan. More than 90% of Taiwanese inhabitants
and medical institutes joined the NHI program. The Na-
tional Health Insurance Research Database (NHIRD) pro-
vides claims and registration datasets for research. In this
study, we used the NHIRD datasets to explore medical uti-
lization and costs of liver cancer patients in Taiwan. The
purpose of this study was to access the annual medical
costs of liver cancer in Taiwan and to determine the factors
that were correlated with the medical costs. The hypoth-
esis of this study was that the medical costs would be
correlated with demographic factors.Methods
Data sources
This is a retrospective cross-sectional study using Longitu-
dinal Health Insurance Database 2005 (LHID2005), which
was obtained from the NHIRD. The LHID2005 contains all
original claim data of 1 million beneficiaries enrolled in
2005 who were randomly sampled from the 2005 Registry
for Beneficiaries of the NHIRD, which contained approxi-
mately 25.68 million individuals [6]. There was no signifi-
cant difference in the distribution of age, gender, and
insured amount between the patients in the LHID2005 and
the original NHIRD. Claims of LHID2005 in 2009 were ob-
tained for analysis. Until 2009, there were 985,628 patients
who remained in this sample. The dropout rate was 1.44%.
Therefore, this sample is very representative of the whole
population. Data in the NHIRD that could be used to identify
patients or care providers such as medical institutions and
physicians were scrambled prior to being sent to theNational Health Research Institutes for database construc-
tion and were further scrambled prior to being released to
each researcher. All data were also de-identified. The study
was approved by the Institutional Review Board of Cheng
Hsin General Hospital in Taipei, Taiwan [CHGH-IRB-(298)].
Study sample
The patients of this study were identified from the
LHIH2005 by diagnosis codes of liver cancer [International
Classification of Diseases, 9th Revision, Clinical modifica-
tion (ICD-9-CM) codes 155 and 155.0-155.2] such as malig-
nant neoplasm of liver and intrahepatic bile ducts [20]. To
obtain demographic information, claim data were linked
with files of registry for beneficiaries by the beneficiaries’
IDs and birthdays. The other beneficiaries without liver
cancer who had used inpatient or outpatient services in
2009 served as the control patients.
Study variables
Dependent variable: cost
In this study, only insurance-covered services were taken
into account. All costs were direct medical costs and pre-
sented in United States dollars [US$; US$1 Z New Taiwan
dollars (NT$) $33.05, based on the average exchange rate in
2009]. The detailed medical expenses in this study include
the medical benefit claims and copayments. The patients’
copayment does not include registration fees. The cate-
gories of “outpatient cost” and “inpatient cost” were based
on the definition by the Bureau of Health Insurance.
Independent variable: age
The age categories were < 50 years, 50e59 years, 60e69
years, 70e79 years, and > 80 years.
Independent variable: income
Income was categorized as US$0, US$1e605, US$606e1210,
and > US$1210. The calculation of income was based on the
insured amount. Dependents were assumed to have no
income.
Independent variable: insured region
Insured regions were divided into four regions, based on
geographic distribution: northern Taiwan, central Taiwan,
southern Taiwan, and eastern Taiwan and offshore islands.
Northern Taiwan was defined as the region extending from
Keelung to Miaoli, which included Yilan. Central Taiwan
included Taichung, Changhua, and Nantou. Southern Taiwan
included the regions extending from Yunglin to Pingtung.
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tung, Penghu, Kinmen, and Mazu.
Independent variable: insured unit
Insured units were categorized by six groups, based on the
definition of the Bureau of Health Insurance.
Statistical analysis
The database software ASIQ 12.5.7 (Sybase Inc, Dublin, CA,
USA) was used for data linkage and processing. The data
were analyzed using SPSS for Windows Version 17.0 (SPSS
Inc., Chicago, IL, USA). The distribution and frequency of
each category of variables were examined by the Krus-
kaleWallis test or by one-way analysis of variance
(ANOVA). A value of p < 0.05 was considered statistically
significant.
Results
In 2009, 2335 patients with liver cancer were identified in
this sample. A total of 2178 (93.3%) patients used outpa-
tient services and 1193 (51.1%) patients used inpatient
services. The control patients comprised 883,804 patients
who had ever used inpatient or outpatient services in 2009.
Medical utilization
Among the patients, 2178 (93.3%) patients used outpatient
services with 76,866 visits (average, 35.3 visits per user)
and 1193 (51.1%) patients used inpatient services with 3153
visits (average 2.6 visits per user). The median frequency
was 31 visits for outpatient users (Fig. 1) and two visits for
inpatient users (Fig. 2).
The most frequently used outpatient service by visit was
Western medicine (85.5%), followed by Chinese medicineFigure 1 Visit frequency of outpatient serv(6.1%), dentistry (3.8%), emergent medicine (3.3%), and
homecare (1.4%) (Table 1). The emergent services had the
highest cost per visit of outpatient services. The most
frequently used inpatient service by visits was ordinary care
(94.0%), followed by other services (4.9%) and hospice care
(0.7%) (Table 1). The hospice care had the lowest cost per
visit of inpatient services.
Medical cost for liver cancer patients and control
patients
The cost for liver cancer patients and the control patients is
presented in Table 2. For liver cancer patients, the cost per
visit was US$59.30 for outpatient services and US$2070.30
for inpatient services. The cost per user was US$2091.70 for
outpatient services and US$5471.6 for inpatient services.
The cost per patient was US$4746.60 with US$1951.00 used
for outpatient services and US$2795.60 used for inpatient
services.
Liver cancer accounted for 1.8% of the total costs, 1.1%
of outpatient costs, and 3.2% of inpatient costs of the NHI.
The average medical cost for liver cancer patients was
higher than that of the control patients. The average costs
per visit of the liver cancer patients was 206.0% of that of
the control patients. The average cost per patient with
liver cancer was 666.8% that of the control patients.
Cost component and service provider
Private hospitals were visited more frequently than public
hospitals for outpatient and inpatient services (Table 3).
The cost per visit was highest in public hospitals for
outpatient services and highest in private hospitals for
inpatient services. Fees for consultation, treatment, and
medical supplies accounted for the highest portion of
outpatient costs (57.3%), followed by drug fees (30.0%), andice use by liver cancer patients in 2009.
Figure 2 The visit frequency of inpatient service use by liver cancer patients in 2009.
Table 1 Medical utilization by liver cancer patients in 2009.
Characteristic Visit % Cost (US$) % Cost per visit (US$)
Outpatient Chinese medicine 4668 6.1 83,801 1.84 18.0
Dentistry 2889 3.8 89,886 1.97 31.1
Emergent medicine 2515 3.3 406,824 8.93 161.8
Homecare 1057 1.4 25,341 0.56 24.0
Western medicine 65,737 85.5 3,949,824 86.70 60.1
Total 76,866 100.0 4,555,675 100 59.3
Inpatient Ordinary care 2963 94.0 5,539,034 84.9 1869.4
Hospice care 23 0.7 14,546 0.2 632.4
Other servicesa 167 4.9 974,074 14.9 5832.8
Total 3153 100 6,527,655 100.0 2070.3
a The data include case payment, special case (cost > NT$500,000.00; vascular stent or transplantation), payment demonstration
program for breast cancer and hepatitis, tuberculosis program, and diet fees for low-income householders.
Table 2 Comparison of the cost for control patients and liver cancer patients in 2009.
Characteristic Control patients a Liver cancer patients %
No. of patients Total 881,469 2335 0.3
Outpatient 880,745 2178 0.2
Inpatient 74,629 1193 1.6
No. of visits Outpatient 14,668,653 76,866 0.5
Inpatient 128,426 3153 2.5
Total cost (US$) Total 627,506,394 11,083,329 1.8
Outpatient 421,993,697 4,555,675 1.1
Inpatient 205,512,697 6,527,655 3.2
Cost per visit (US$) Outpatient 28.8 59.3 206.0
Inpatient 1600.2 2070.3 129.4
Average cost per user (US$) b Outpatient 479.1 2091.7 436.6
Inpatient 2753.8 5471.6 198.7
Cost per patient (US$) c Total 711.9 4746.6 666.8
Outpatient 478.7 1951.0 407.5
Inpatient 233.1 2795.6 1199.1
a All patients who ever used outpatient or inpatients services in this sample database.
b Outpatient cost divided by outpatient service users; inpatient cost divided by the number of inpatient service users.
c The cost divided by the number of all liver cancer patients or control participants.
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Table 3 Cost and service providers for patients with liver cancer in 2009.
Characteristic Public
hospitals
Private
hospitals
Public
clinics
Private
clinics
Nursing
institutions
Total %
Outpatient Visit 16,198 31,173 1313 28,088 94 76,866
Cost (US$) Drug fees 473,050 805,676 10,340 76,427 199 1,365,692 30.0
Consultation, treatment,
and medical supplies
706,417 1,410,737 4295 480,414 6495 2,608,359 57.3
Diagnosis fees 102,246 192,992 9166 203,856 61 508,322 11.2
Dispensing service fees 20,871 39,484 912 12,032 4 73,303 1.6
Total 1,302,584 2,448,889 24,714 772,729 6758 4,555,675 100.0
Average cost per visit 80.4 78.6 18.8 27.5 71.9 59.3
Inpatient Visit 1075 2078 3153
Cost (US$) Diagnosis fees 118,076 237,067 355,143 5.4
Ward fees 406,677 832,322 1,238,999 19.0
Tube feeding fees 9991 24,333 34,324 0.5
Laboratory fees 234,987 445,798 680,785 10.4
X-ray fees 307,755 665,261 973,017 14.9
Therapeutic procedure fees 114,646 256,952 371,597 5.7
Surgical fees 99,382 279,293 378,675 5.8
Rehabilitation fees 5520 7160 12,679 0.2
Hemodialysis fees 27,577 41,042 68,619 1.1
Blood/plasma fees 112,569 245,457 358,027 5.5
Anesthesia fees 39,321 78,105 117,426 1.8
Special materials fees 157,023 418,265 575,289 8.8
Drug fees 336,760 885,711 1,222,471 18.7
Dispensing service fees 30,500 58,682 89,182 1.4
Psychiatric treatment fees 1752 3594 5347 0.1
Injection technology fees 14,847 31,227 46,074 0.7
Total 2,017,384 4,510,271 6,527,655 100.0
Average cost per visit (US$) 1876.6 2170.5 2070.3
50 C. Yeh et al.diagnosis fees (11.2%). Ward fees accounted for the highest
portion of inpatient cost (19.0%), followed by drug fees
(18.7%), and X-ray fees (14.9%).
Demographics
The correlation between cost and demographic character-
istics is presented in Table 4. A greater proportion of liver
cancer patients was male, in their 50s, earned a monthly
middle income (US$606.00e1210.00), lived in northern
Taiwan, or were dependents. Patients had a higher cost per
patient if they were female, in their 60s, earned no income
(by insured amount), lived in southern Taiwan, and lived in
low-income households (by insured unit) (p < 0.0001). The
correlation between cost and age was further analyzed
(Table 5). The patients in their 60s had a higher cost per
visit for outpatient and inpatient services.
Discussion
Liver cancer is the third leading cause of cancer-related
deaths in the world [1]. However, information on the eco-
nomic burden of liver cancer is limited. This study is the
first to evaluate the annual medical costs of liver cancer in
Taiwan. Our data can serve as an important reference for
health care providers and policymakers. Using the NHI data,
our study assessed the medical utilization and costs of livercancer patients who used medical services in 2009. The NHI
in Taiwan is a comprehensive and universal health insur-
ance program, which has provided Western medicine, Chi-
nese medicine, dental care, and hospital care since 1995.
Until 2009, the NHI covered more than 99% of residents and
92% of medical institutions in Taiwan. Therefore, the claim
and registration datasets of the NHI are an ideal tool to
investigate the utilization of medical services of the studied
population.
In this study, we used sample datasets containing 1
million NHI beneficiaries. A total of 2335 liver cancer pa-
tients were identified. All claims of liver cancer patients
were collected for analysis. Therefore, the study results
were representative.
This study found that liver cancer patients accounted for
0.3% of medical service users, 0.2% of outpatient service
users, and 1.6% of inpatient service users. However, liver
cancer accounted for 1.8% of the total medical costs, 1.1% of
outpatient costs, and 3.2% of inpatient costs for all benefi-
ciaries. The average medical costs were higher for liver
cancer patients than for the control patients. Liver cancer
patients used more medical resources. Since 1984, there has
been a successful universal vaccination plan for HBV for
newborns in Taiwan. The average incidence of liver cancer
per 100,000 children decreased from 0.7 in 1981e1986 to
0.36 in 1990e1994 in children 6e14 years old. However, the
lower incidence of liver cancer in adults will be effected
after 3e4 decades [7,8]. Liver cancer remains a heavy
Table 4 The correlation between the cost and the demographic characteristics of liver cancer patients in 2009.
Characteristics No. of patients a % Average cost per patient (US$) p b
Outpatient Inpatient Total
Gender < 0.0001
Female 818 35.1 1964 3031 4995
Male 1515 64.9 1930 2367 4298
Age (y) < 0.0001
< 50 425 18.2 1322 1682 3003
50s 575 24.6 1995 3111 5105
60s 563 24.1 2223 3332 5555
70s 543 23.3 2199 2725 4924
> 80 227 9.7 1764 2946 4710
Income (US$/mo) c < 0.0001
0 665 28.5 2301 2670 4972
1e605 419 18.0 1869 2917 4786
606e1210 991 42.5 1874 2926 4800
> 1210 258 11.1 1489 2443 3932
Insured region < 0.0001
Northern Taiwan 1057 45.3 1631 2365 3996
Central Taiwan 358 15.3 2521 2681 5201
Southern Taiwan 846 36.3 2127 3442 5569
Eastern Taiwan and offshore islands 72 3.1 1791 2171 3962
Insured unit < 0.0001
Employees of government, schools,
enterprises, or institutions
423 18.1 1442 2492 3934
Members of occupational unions
and alien seamen
345 14.8 1907 3114 5020
Farmers and fishermen 534 22.9 1975 2853 4828
Low-income households 30 1.3 1722 3892 5614
Veterans and other regional population 336 14.4 1934 2927 4861
Dependents 665 28.5 2301 2670 4972
a Two patients with missing demographic data were excluded.
b The p value of the total cost, based on the KruskaleWallis test.
c The calculation of income was based on the insured amount. Dependents were assumed to have no income.
Medical utilization by liver cancer patients 51burden on the health system in Taiwan. Therefore, the
development of cost-effective treatment strategies for liver
cancer is critical to reduce the financial burden in Taiwan.
It is difficult to compare the cost in different studies
because of heterogeneity across studies in the settings,
populations studied, measurement of costs, and study
methods. Lang et al [9] conducted a claim data analysis
from a medical center in Taiwan and found that the 10-year
lifetime average cost of patients with liver cancer was
NT$418,554.00 [New Taiwan dollars (NT$) Z US
$12,683.00]. The Huang study [10] used the NHI data from
1996 to 2002 with ICD-9 code 155. For all incident cases of
liver cancer in 1997, the average 5-year cumulated cost was
NT$219,398.00 (US $6648.00).
The prognosis of liver cancer is poor. The 1-year and 5-
year overall survival rate of liver cancer in Taiwan is 48.98%
and 19.72%, respectively [11]. In this study, the average
cost per patient was US$4746.60 in 2009. Lang et al [12]
found the overall per patient cost of liver cancer was
US$32,907.00 in the United States of America (USA) with
US$29,354.00 spent on health care cost and US$3553.00
spent on the value of lost productivity. Our study found that
the annual overall per patient cost of liver cancer was
US$4746.60 in Taiwan. The per patient monthly cost wasUS$7845.00 in the USA and US$395.60 in Taiwan. The cost of
liver cancer is much lower in Taiwan than in the USA;
however, the 5-year survival rate of liver cancer is better in
Taiwan than in the USA [11,13]. Taiwan’s medical system
provided efficiency and quality medical services. Taiwan’s
NHI system has attracted attention from around the world
for its many achievements such as its universality, ability to
care for socially and economically disadvantaged groups,
and a wide range of coverage and consistent level of
quality. Physician visits per person per year was 13.9 in
Taiwan, 3.8 in the USA, 7.5 in Germany, and five in the
United Kingdom [14]. The average life expectancy and in-
fant mortality rate in Taiwan were compatible with those in
Economic Co-operation and Development (OECD) countries.
The utilization of medical services increased, although the
health expenditure remained at 6.1% of the gross domestic
product (GDP) in Taiwan [14]. This finding is in sharp
contrast with the USA (16% of the GDP) and lower than that
of most OECD countries [15].
The correlation was analyzed between cost and medical
utilization, demographics, and service providers. The most
frequently used outpatient services by visits was Western
medicine (85.5%), followed by Chinese medicine (6.1%).
Our previous study [16] in 2007 found that 3.9% patients
Table 5 Correlation between cost (average cost per patient) and age of patients with liver cancer in 2009. (In US$).
Variable < 50 y 50e59 y 60e69 y 70e79 y > 80 y p a
Outpatient No. of patients 425 575 563 543 227
Visits 10,971 167,39 20,844 20,917 7359
Average visit per patient 25.8 29.1 37.0 38.5 32.4
Drug fees 402 576 737 627 476 0.0146
Consultation, treatment and medical supplies 722 1203 1210 1279 1027 0.0109
Diagnosis fees 177 190 240 253 226 0.0000
Dispensing service fees 20 26 35 40 35 0.0000
Total 1322 1995 2223 2199 1764 0.0001
Inpatient No. of patients 425 575 563 543 227
Visits 402 755 832 801 363
Average visit per patient 0.9 1.3 1.5 1.5 1.6
Diagnosis fees 98 148 174 158 198 0.0000
Ward fees 318 506 611 564 715 0.0000
Tube feeding fees 4 8 16 20 34 0.0016
Laboratory fees 173 306 337 299 350 0.0001
X-ray fees 275 453 482 445 365 0.0017
Therapeutic procedure fees 76 140 195 163 264 0.0009
Surgical fees 119 242 198 114 68 0.0035
Rehabilitation fees 1 2 14 3 6 0.2540
Hemodialysis fees 7 27 44 39 19 0.6229
Blood/plasma fees 87 190 200 124 138 0.0120
Anesthesia fees 43 63 60 41 29 0.0252
Special materials fees 137 240 302 293 218 0.0000
Drug fees 294 724 631 404 469 0.0279
Dispensing service fees 27 39 43 38 47 0.0016
Psychiatric treatment fees 8 3 0 0 0 0.0696
Injection technology fees 13 20 23 19 26 0.0648
Total 1682 3111 3332 2725 2946 0.0003
a Based on the one-way analysis of variance (ANOVA) test.
52 C. Yeh et al.with liver cancer (with diagnosis codes 155 and 155.0) used
cancer-related outpatient services of Chinese medicine
(CM) at least once. Chinese medicine accounted for 2.6%
visits and 0.7% expenditure of ambulatory services for liver
cancer. Western medicine is the mainstream. In liver can-
cer care, CM has more a complementary role than an
alternative role. Our results also demonstrated that hospice
care had the lowest average cost per inpatient service visit.
This is consistent with a previous study in Taiwan [17].
Our study demonstrated that the cost of liver cancer
care to the NHI varied by sex, age, income, and geographic
distribution. A higher proportion of liver cancer patients
were male, in their 50s, earned a monthly middle income
(US$606eUS$1210), and lived in northern Taiwan, or were
dependents. However, patients who were female, in their
60s, earned no income (by the insured amount), lived in
southern Taiwan, or were from low-income households
(by insured unit) had a higher average cost per patient
(p < 0.0001). The role of HBV and HCV in liver cancer in
Taiwan differs in different age groups. Hepatitis B virus
was more frequent in young liver cancer patients, and HCV
was more frequent in elderly liver cancer patients in
Taiwan [18]. Chen et al [19] found that HCV infection was
very common in some villages and townships in southern
Taiwan [19]. Our study also found that patients in their 60s
had a higher cost per visit for outpatient and inpatient
services.Several limitations of this study must be acknowledged.
(1) This is a claim-based study; only insurance-covered
services and medications were taken into account. Out-of-
pocket herbal medicine and noncontracted medical in-
stitutes were not included. This may underestimate the
cost. (2) The cost was the points that the contracted
medical institutions declared and was not corrected for the
point value by global budget payment and deduction by
NHI. The NHI paid medical fees to health care providers on
a fee-for-service basis. The global budget payment scheme
was promoted from dental services to CM, followed by
Western medicine primary care, and finally hospitals. The
system was universally implemented in all medical care
institutions by July 2002. The point value by global budget
payment system is floating. In 2009, one point value was
equal to NT$0.8872e1.0002. Furthermore, the service costs
to be deducted by NHI were not adjusted. Adjusting the
point value and deduction would decrease the cost by
approximately 10%. (3) The study population was selected
by the diagnosis codes. The number of liver cancer patients
may be overestimated because of overcoding. (4) The
NHIRD is primarily for administrative purposes. The clinical
characteristics such as staging and biochemical data were
unavailable. The disease severity and survival could not be
evaluated in this study. The cost effectiveness could not be
analyzed. (5) This study included all medical services for
analysis, regardless of their relevance to the liver cancers.
Medical utilization by liver cancer patients 53Among the services that liver cancer patients utilized, some
services were not relevant to the liver cancer. Some ser-
vices were relevant to the liver cancer. Some services were
not directly relevant to the liver cancers, but may be
contributed to or accounted for by the disease. This may
overestimate the cost.
This study was designed to explore the economic burden
of liver cancer in Taiwan. The methods of treatment, dis-
ease severity, and type of hospital influence the differences
in the health care costs between patients or between
geographical regions. In a cross-sectional study, this sample
is not well reflective of the whole course of liver cancer.
Therefore, the aforementioned factors were not analyzed.
In the future, a longitudinal study is warranted to explore
these important factors.
In conclusion, liver cancer is a heavy burden on the
health service system in Taiwan. Liver cancer patients used
more medical resources than the other people. The cost of
liver cancer care is substantial and varies by sex, age, in-
come, and geographic distribution. Based on the findings of
the study, it is critical to reduce the incidence of liver
cancer and identify cost-effective treatment strategies.
Conflicts of interest
All authors declare no conflicts of interest.
Acknowledgments
This study is based in part on data from the National Health
Insurance Research Database provided by the Bureau of
National Health Insurance, the Department of Health, and
managed by the National Health Research Institutes. The
interpretations and conclusions contained in this paper do
not represent those of the Bureau of National Health In-
surance, Department of Health, or National Health
Research Institutes. This work was supported by Cheng Hsin
General Hospital in Taipei, Taiwan (grant number 102-35).
References
[1] Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics,
2002. CA Cancer J Clin 2005;55:74e108.
[2] Lok AS, Seeff LB, Morgan TR, di Bisceglie AM, Sterling RK,
Curto TM, et al., HALT-C Trial Group. Incidence of hepato-
cellular carcinoma and associated risk factors in hepatitis C-
related advanced liver disease. Gastroenterology 2009;136:
138e48.[3] McGlynn KA, Tarone RE, El-Serag HB. A comparison of trends in
the incidence of hepatocellular carcinoma and intrahepatic
cholangiocarcinoma in the United States. Cancer Epidemiol
Biomarkers Prev 2006;15:1198e203.
[4] Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular car-
cinoma incidence, mortality, and survival trends in the United
States from 1975 to 2005. J Clin Oncol 2009;27:1485e91.
[5] Bureau of Health Promotion. Department of Health. 2009
Annual report. Taipei, Taiwan: Bureau of Health Promotion;
2009.
[6] National Health Insurance Research Database. 2014. Available
at: http://nhird.nhri.org.tw/en/index.htm [accessed
09.02.14].
[7] Kao JH, Chen DS. Global control of hepatitis B virus infection.
Lancet Infect Dis 2002;2:395e403.
[8] Kao JH, Chen DS. Changing disease burden of hepatocellular
carcinoma in the Far East and Southeast Asia. Liver Int 2005;
25:696e703.
[9] Lang HC, Wu JC, Yen SH, Lan CF, Wu SL. The lifetime cost of
hepatocellular carcinoma: a claims data analysis from a
medical centre in Taiwan. Appl Health Econ Health Policy
2008;6:55e65.
[10] Huang CF. Medical cost and treatment outcome related fac-
tors for HCC. In: Institute of Health Care Management.
Kaohsiung: National Sun Yat-sen University; 2005. p. 97.
[11] Bureau of Health Promotion. Department of Health. Executive
Yuan. Cancer registry annual report, 2007. Taipei, Taiwan:
Bureau of Health Promotion; 2010.
[12] Lang K, Danchenko N, Gondek K, Shah S, Thompson D. The
burden of illness associated with hepatocellular carcinoma in
the United States. J Hepatol 2009;50:89e99.
[13] Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer
statistics, 2008. CA Cancer J Clin 2008;58:71e96.
[14] Bureau of National Health Insurance. National Health Insur-
ance in Taiwan 2010. Taipei, Taiwan: Bureau of Health Pro-
motion; 2010.
[15] Organisation for Economic Co-operation and Development
(OECD). OECD health data 2009 e Statistics and indicators for
30 countries. Paris, France: OECD; 2009.
[16] Lin YH, Chiu JH. Use of Chinese medicine among patients with
liver cancer in Taiwan. J Altern Complement Med (New York,
NY) 2010;16:527e8.
[17] Lin WY, Chiu TY, Hsu HS, Davidson LE, Lin T, Cheng KC, et al.
Medical expenditure and family satisfaction between hospice
and general care in terminal cancer patients in Taiwan. J
Formos Med Assoc [Taiwan Yi Zhi] 2009;108:794e802.
[18] Chen DS. Hepatocellular carcinoma in Taiwan. Hepatol Res
2007;37(Suppl. 2):S101e5.
[19] Chen DS. Viral hepatitis in East Asia. J Formos Med Assoc
[Taiwan Yi Zhi] 1996;95:6e12.
[20] U.S. Centers for Disease Control and Prevention. International
classification of diseases, ninth revision, clinical modification
(ICD-9-CM). 2014. Available at: http://www.cdc.gov/nchs/
icd/icd9cm.htm [accessed 09.02.14].
